Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity

Mayo Clinic Proceedings - Tập 79 - Trang 875-882 - 2004
Paul Richardson1, Robert Schlossman1, Sundar Jagannath2, Melissa Alsina3, Raman Desikan2, Emily Blood1, Edie Weller1, Constantine Mitsiades1, Teru Hideshima1, Faith Davies1, Deborah Doss1, Andrea Freeman1, Joan Bosch4, John Patin4, Robert Knight4, Jerome Zeldis4, William Dalton3, Kenneth Anderson1
1Division of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Mass
2St Vincents Catholic Medical Center, New York, NY
3Lee Moffitt Cancer Center, Tampa, Fla.
4Celgene Corporation, Warren, NJ

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Mayo Clinic Proceedings

Tập 79

875-882

Thông tin tác giả